logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
R

Richard G. Moore

university of rochester
H指数:53
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lenvatinib Plus Pembrolizumab in Participants With Advanced or Recurrent Endometrial Cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 Post-(Neo)Adjuvant Therapy Outcomes

Lenvatinib联合Pembrolizumab在晚期或复发性子宫内膜癌患者中的应用：Study 309/KEYNOTE-775和ENGOT-en9/LEAP-001术后（新辅助）治疗结局

International Journal of Gynecological Cancer
IF4.7
2026-04-120
PRE
Christian Marth; Domenica Lorusso; Mariusz Bidziński; Paolo Scollo; Mehmet Ali Vardar; Ana Oaknin; Diego Lucas Kaen; Angélica Nogueira-Rodrigues; David S. Miller; Kosei Hasegawa; Helen MacKay; Richard G. Moore; Alessandro D. Santin; Mayu Yunokawa; Ignacio Romero; Sandro Pignata; Sally Baron-Hay; Yong Man Kim; Amnon Amit; Sharad Ghamande
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: 1-Year Follow-Up After Final Analysis of the ENGOT-en9/LEAP-001 Phase 3 Trial

一线仑伐替尼联合帕博利珠单抗与化疗治疗晚期子宫内膜癌：ENGOT-en9/LEAP-001 III期试验最终分析后的1年随访

International Journal of Gynecological Cancer
IF4.7
2025-11-110
PRE
Christian Marth; Richard G. Moore; Mariusz Bidziński; Vanda Salutari; Özden Altundağ; Maria Jesús Rubio; Tally Levy; Alison Stillie; Christof Vulsteke; Ralf Witteler; Kazuya Ariyoshi; Xiaohua Wu; Sophia Frentzas; André Mattar; Brian M. Slomovitz; Stephanie Lheureux; Xiaojun Chen; Kosei Hasegawa; Manuel Magallanes; Chel Hun Choi
A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO

在一项关于 niraparib 联合 bevacizumab 维持治疗的研究中，该研究在晚期卵巢癌患者接受以 bevacizumab 辅助的一线铂类化疗后进行，报告了 OVARIO 研究的最终分析结果及总生存数据。

gynecologic oncology
IF4.1
2025-07-010
OA
Melissa M. Hardesty; Thomas C. Krivak; Gail S. Wright; Erika Hamilton; Evelyn L. Fleming; Jimmy Belotte; Shelby Gorman; Natalie Compton; Aine Clements; Heidi J. Gray; Gottfried E. Konecny; Richard G. Moore; Debra L. Richardson
Dostarlimab and niraparib in primary advanced ovarian cancer

多斯塔利姆单抗和尼拉帕利在原发性晚期卵巢癌中的应用

Annals of Oncology
IF65.4
2025-06-020
OAAI
A.-C. Hardy-Bessard; E. Pujade-Lauraine; R.G. Moore; F. Montestruc; A. Redondo; M.R. Mirza; D. Cibula; T.-E. Ciuleanu; L. Gilbert; R. Eitan; F. Zagouri; S. Pignata; R. Glasspool; J. Pfisterer; R. Phaëton; C.K. Anderson; M. Rodrigues; L. Gaba; E. Bakirtzi; J.M. Fauci; E. Kalbacher; F.B. Musa; S. Gorman; L.R. Duska; L. Gladieff; P. Braly; F. Joly; J. Thomes Pepin; I. Ray-Coquard; K.N. Moore
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ ENGOT-OV26/GOG-3012 trial

新诊断晚期卵巢癌患者的尼拉帕尼一线维持治疗: PRIMA/ ENGOT-OV26/GOG-3012试验的最终总生存期结果

ANNALS OF ONCOLOGY
IF65.4
2024-11-012
OAAI
Monk, B. J.; Barretina-Ginesta, M. P.; Pothuri, B.; Vergote, I.; Graybill, W.; Mirza, M. R.; Mccormicky, C. C.; Lorusso, D.; Moore, R. G.; Freyer, G.; O'Cearbhaill, R. E.; Heitz, F.; O'Malley, D. M.; Redondo, A.; Shahin, M. S.; Vulsteke, C.; Bradley, W. H.; Haslund, C. A.; Chase, D. M.; Pisano, C.; Holman, L. L.; Perez, M. J. Rubio; Disilvestro, P.; Gaba, L.; Herzog, T. J.; Bruchim, I.; Compton, N.; Shtessel, L.; Malinowska, I. A.; Gonzalez-Martin, A.
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary

随访3.5年时的无进展生存期和安全性: 对新诊断卵巢癌患者进行尼拉帕尼维持治疗的3期PRIMA/ENGOT-OV26/GOG-3012随机试验的结果-简明语言总结

FUTURE ONCOLOGY
IF2.6
2024-03-191
OAAI
Gonzalez-Martin, Antonio; Pothuri, Bhavana; Vergote, Ignace; Graybill, Whitney; Lorusso, Domenica; McCormick, Colleen C.; Freyer, Gilles; Backes, Floor; Heitz, Florian; Redondo, Andres; Moore, Richard G.; Vulsteke, Christof; O'Cearbhaill, Roisin E.; Malinowska, Izabela A.; Shtessel, Luda; Compton, Natalie; Mirza, Mansoor R.; Monk, Bradley J.
Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer
BRITISH JOURNAL OF CANCER
IF6.8
2024-01-093
OA
Han, Chae Young; Bedia, Jacob S.; Yang, Wei-Lei; Hawley, Sarah J.; Bergan, Lindsay; Hopper, Marika; Celestino, Joseph; Guo, Jing; Gornet, Terrie G.; Soosaipillai, Antoninus; Yang, Hailing; Doskocil, Samantha D.; Lokshin, Anna E.; Handy, Beverly C.; Diamandis, Eleftherios P.; Moore, Richard G.; Lu, Karen H.; Lu, Zhen; Anderson, Karen S.; Drescher, Charles W.; Skates, Steven J.; Bast Jr, Robert C.
Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa)
ANNALS OF ONCOLOGY
IF65.4
2023-10-013
PRE
Liu, J. F.; Brady, M.; Matulonis, U. A.; Miller, A.; Kohn, E. C.; Swisher, E.; Tew, W.; Cloven, N.; Muller, C.; Bender, D.; Moore, R.; Michelin, D.; Waggoner, S.; Geller, M.; Fujiwara, K.; D'Andre, S.; Carney, M.; Secord, A. A.; Walker, J.; Bookman, M. A.
Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/ paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial
ANNALS OF ONCOLOGY
IF65.4
2023-10-017
PRE
Eskander, R. N.; Sill, M.; Miller, A.; Beffa, L.; Moore, R.; Hope, J.; Musa, F.; Mannel, R.; Shahin, M. S.; Canturia, G.; Girda, E.; Mathews, C.; Kavecansky, J.; Leath, C. A., III; Gien, L.; Hinchcliff, E.; Lele, S.; Powell, M. A.; Aghajanian, C.
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer

随访3.5年时的无进展生存期和安全性: 对新诊断卵巢癌患者进行尼拉帕尼维持治疗的3期PRIMA/ENGOT-OV26/GOG-3012随机试验的结果

EUROPEAN JOURNAL OF CANCER
IF7.1
2023-08-0141
OA
Gonzalez-Martin, Antonio; Pothuri, Bhavana; Vergote, Ignace; Graybill, Whitney; Lorusso, Domenica; McCormick, Colleen C.; Freyer, Gilles; Backes, Floor; Heitz, Florian; Redondo, Andres; Moore, Richard G.; Vulsteke, Christof; O'Cearbhaill, Roisin E.; Malinowska, Izabela A.; Shtessel, Luda; Compton, Natalie; Mirza, Mansoor R.; Monk, Bradley J.
Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer
OBSTETRICAL & GYNECOLOGICAL SURVEY
IF3.6
2023-07-011
PRE
Eskander, Ramez N.; Sill, Michael W.; Beffa, Lindsey; Moore, Richard G.; Hope, Joanie M.; Musa, Fernanda B.; Mannel, Robert; Shahin, Mark S.; Cantuaria, Guilherme H.; Girda, Eugenia; Mathews, Cara; Kavecansky, Juraj; Leath, Charles A.; Gien, Lilian T.; Hinchcliff, Emily M.; Lele, Shashikant B.; Landrum, Lisa M.; Backes, Floor; O'Cearbhaill, Roisin E.; Al Baghdadi, Tareq; Hill, Emily K.; Thaker, Premal H.; John, Veena S.; Welch, Stephen; Fader, Amanda N.; Powell, Matthew A.; Aghajanian, Carol
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
NEW ENGLAND JOURNAL OF MEDICINE
IF78.5
2023-06-08246
OA
Eskander, Ramez N.; Sill, Michael W.; Beffa, Lindsey; Moore, Richard G.; Hope, Joanie M.; Musa, Fernanda B.; Mannel, Robert; Shahin, Mark S.; Cantuaria, Guilherme H.; Girda, Eugenia; Mathews, Cara; Kavecansky, Juraj; Leath III, Charles A.; Gien, Lilian T.; Hinchcliff, Emily M.; Lele, Shashikant B.; Landrum, Lisa M.; Backes, Floor; O'Cearbhaill, Roisin E.; Al Baghdadi, Tareq; Hill, Emily K.; Thaker, Premal H.; John, Veena S.; Welch, Stephen; Fader, Amanda N.; Powell, Matthew A.; Aghajanian, Carol

研究方向

暂未获取到该数据
N
Naohiro Yano
H 指数:30论文数:148被引数:2,367
K
Kyu Kwang Kim
H 指数:20论文数:66被引数:1,636
M
Michael Craig Miller
H 指数:49论文数:277被引数:2.3万
N
Negar Khazan
H 指数:8论文数:38被引数:248
R
Roisin E. O’Cearbhaill
H 指数:38论文数:402被引数:8,192
R
Rakesh K. Singh
H 指数:21论文数:114被引数:2,189
J
Jennifer R. Ribeiro
H 指数:17论文数:142被引数:780
S
Shashikant Lele
H 指数:46论文数:263被引数:1.1万
L
Louise A. Brinton
H 指数:126论文数:970被引数:6.4万
D
David G. Mutch
H 指数:99论文数:980被引数:4.7万